Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-38.02%
0%
-38.02%
6 Months
-18.21%
0%
-18.21%
1 Year
-57.65%
0%
-57.65%
2 Years
-57.65%
0%
-57.65%
3 Years
-84.3%
0%
-84.3%
4 Years
-92.56%
0%
-92.56%
5 Years
-96.74%
0%
-96.74%
Venus Medtech (Hangzhou), Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.30%
EBIT Growth (5y)
-26.59%
EBIT to Interest (avg)
-46.93
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
0.12
Tax Ratio
1.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.69
EV to EBIT
-1.99
EV to EBITDA
-2.33
EV to Capital Employed
0.62
EV to Sales
3.47
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-31.01%
ROE (Latest)
-47.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Dec 2021
Shareholding Compare (%holding) 
Majority shareholders
Non Institution
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 197 Foreign Institutions (20.92%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
472.70
501.20
-5.69%
Operating Profit (PBDIT) excl Other Income
-669.40
-277.40
-141.31%
Interest
51.90
2.30
2,156.52%
Exceptional Items
424.10
584.80
-27.48%
Consolidate Net Profit
-1,304.80
-447.60
-191.51%
Operating Profit Margin (Excl OI)
-1,692.60%
-677.70%
-101.49%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is -5.69% vs 61.57% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is -191.51% vs -117.81% in Dec 2021
About Venus Medtech (Hangzhou), Inc. 
Venus Medtech (Hangzhou), Inc.
Medical Specialties
No Details Available.
Company Coordinates 
No Company Details Available






